On December 27, 2019 Geneseeq, a Nanjing-Toronto company that offers genetic sequencing tests for cancer, reported that it has completed a $114 million Series D financing led by China Reform Holdings Corporation (Press release, Geneseeq, DEC 27, 2019, View Source [SID1234553212]). Geneseeq uses next-gen sequencing to provide decision-making tools for physicians. The company describes its pan-genomic test as a precision medicine support system for targeted drugs, immunotherapies and cancer risk assessment. The Geneseeq Prime test detects genetic abnormalities in 425 cancer-related genes. Lilly Asia Ventures and SoftBank China Venture Capital also participated in this round. In the three previous fundings, Geneseeq raised a total of $86 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!